News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aerovate Therapeutics Inc
(NQ:
AVTE
)
1.780
-0.010 (-0.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aerovate Therapeutics Inc
< Previous
1
2
3
4
Next >
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q2 2024
August 12, 2024
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Aerovate Therapeutics to Explore Strategic Alternatives
July 08, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
The 3 Hottest Stock Downgrades From Last Week
June 27, 2024
Explore the experts' latest surprising stock downgrades amid significant market shifts and analyst adjustments.
Via
InvestorPlace
Nasdaq Surges Over 200 Points; Aaron's Shares Jump
June 17, 2024
Via
Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
June 17, 2024
Via
Benzinga
Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
June 17, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why 90% Of Aerovate Therapeutics' Value Just Went Up In Smoke
June 17, 2024
The company was working on a treatment for pulmonary arterial hypertension, a form of high blood pressure in the lungs.
Via
Investor's Business Daily
Why Is Small Cap-Heart Disease Focused Aerovate Therapeutics Stock Plummeting On Monday?
June 17, 2024
Aerovate Therapeutics shares dropped 90.4% following the release of Phase 2b trial results for AV-101 for pulmonary arterial hypertension. Despite being well tolerated, AV-101 failed to meet primary...
Via
Benzinga
US Stocks Mixed; Dow Tumbles Over 100 Points
June 17, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Recap: Aerovate Therapeutics Q4 Earnings
March 25, 2024
Via
Benzinga
Recap: Aerovate Therapeutics Q3 Earnings
November 13, 2023
Via
Benzinga
Recap: Aerovate Therapeutics Q1 Earnings
May 15, 2023
Via
Benzinga
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
June 17, 2024
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
May 21, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024
May 13, 2024
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
May 13, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Ermenegildo Zegna Reports FY23 Results, Joins Altice USA, Herbalife And Other Big Stocks Moving Lower On Friday
April 05, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Friday. Shares of Ermenegildo Zegna N.V. (NYSE: ZGN) fell sharply during Friday’s session as the company reported FY23...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
March 27, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023
March 25, 2024
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
March 25, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
March 06, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
November 20, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
November 13, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
August 14, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
July 11, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
June 01, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
May 22, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
May 15, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
March 29, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.